Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CStone Signs $363 Million Deal for Rights to LegoChem ADC Candidate

publication date: Oct 29, 2020

CStone Pharma of Suzhou acquired global rights (ex-Korea) in a $363.5 million deal to a novel antibody drug conjugate from LegoChem Biosciences. CStone will pay $10 million upfront and up to $353.5 million in milestones. The candidate, LCB71, targets ROR1 (receptor tyrosine kinase-like orphan receptor 1), a high-potential ADC target for various forms of leukemia, non-Hodgkin lymphoma, plus breast, lung, and ovarian cancers. The companies believe LCB71 has first-in-class/best-in-class potential. More details....

Stock Symbols: (HK: 2616) (KOSDAQ: 141080)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.